Arizona
Phoenix; BCG Oncology
The main purpose of this research study is to evaluate the safety and dosing of an investigational gene transfer agent called CG0070 and to see if it has an effect on superficial bladder cancer that does not respond to prior BCG (bacillus Calmette-Guerin) treatment.
California
BEVERLY HILLS; FOUNDATION/ TOWER HEMATOLOGY ONCOLOGY
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Beverly Hills; Foundation/ Tower Hematology Oncology
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Beverly Hills; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Duarte; City of Hope
Bladder Cancer Database
LA JOLLA; REBECCA AND JOHN MOORES UCSD CANCER CENTER
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
La Jolla; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Los Angeles; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
San Francsico; UCSF Comprehensive Cancer Center
The main purpose of this research study is to evaluate the safety and dosing of an investigational gene transfer agent called CG0070 and to see if it has an effect on superficial bladder cancer that does not respond to prior BCG (bacillus Calmette-Guerin) treatment.
Santa Monica; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Stanford; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Vallejo; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Colorado
Denver; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Connecticut
New Haven; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Florida
Atlanta; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Jacksonville; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
MIAMI; ADVANCED MEDICAL SPECIALTIES
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Miami; Advanced Medical Specialties
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Miami; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Georgia
MACON; CENTRAL GA CANCER CARE, P.C.
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Macon; Central Ga Cancer Care, P.C.
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Savannah; Memorial Health University Medical Center
SWOG S0306: A Phase II Study of Irinotecan in Patients
with Advanced Transitional Cell Carcinoma of the Urothelium
Hawaii
Honolulu; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Illinois
CHICAGO; UNIVERSITY OF CHICAGO MEDICAL CENTER
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Chicago; University Of Chicago Medical Center
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Chicago; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Maywood; Loyola University Medical Center Clinical Trials Office
A multicenter trial of adjuvant chemotherapy in organ-confined Bladder Cancer based on p53 status
SPRINGFIELD; SPRINGFIELD CLINIC
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Springfield; Springfield Clinic
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Urbana; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Kentucky
Louisville; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Maryland
Baltimore; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Massachusetts
Burlington; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Michigan
Ann Arbor; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Detroit; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Missouri
Columbia; University Of Missouri Healthcare/Ellis Fischel Cancer Ctr.
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
KANSAS CITY; KANSAS CITY CANCER CENTER
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
KANSAS CITY; KANSAS CITY VA MEDICAL CENTER
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Kansas City; Kansas City Va Medical Center
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Kansas City; Kansas City Cancer Center
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Kansas City; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
St. Louis; Washington University School Of Medicine
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
St. louis; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Montana
BILLINGS; BILLINGS CLINIC
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
BILLINGS; HEMATOLOGY ONCOLOGY CENTERS OF THE NORTHERN ROCKIES
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Billings; Hematology Oncology Centers Of The Northern Rockies
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Billings; Billings Clinic
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Billings; Billings Clinic
The main purpose of this research study is to evaluate the safety and dosing of an investigational gene transfer agent called CG0070 and to see if it has an effect on superficial bladder cancer that does not respond to prior BCG (bacillus Calmette-Guerin) treatment.
Nevada
Cooperstown; The Mary Imogene Bassett Hospital
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Las Vegas; Nevada Cancer Institute
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
New Hampshire
Lebanon; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
New Jersey
HACKENSACK; THE CANCER CENTER @ HACKENSACK UNIVERSITY MEDICAL CENTER
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Lawrenceville; AdvanceMed Research
Bladder Cancer
New York
Albany; New York Oncology Hematology
The main purpose of this research study is to evaluate the safety and dosing of an investigational gene transfer agent called CG0070 and to see if it has an effect on superficial bladder cancer that does not respond to prior BCG (bacillus Calmette-Guerin) treatment.
Bronx; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
COOPERSTOWN; THE MARY IMOGENE BASSETT HOSPITAL
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Lake Success; Biomedical Research Alliance of New York
Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer - Adults
Lake Success; Biomedical Research Alliance of New York
Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer - Adults
New Hyde Park; Biomedical Research Alliance of New York
Bladder Cancer- Adults
New York; Columbia University Medical Center
This study involves the injection of certain peptides and an immune system stimulating substance to try to stimulate the immune system to recognize and kill tumor cells.
New York; Mount Sinai Medical Center
A Randomized, Comparative, Controlled Phase III, Multicenter Study of Hexvix Fluorescence Cystoscopy and White Light Cystoscopy in the Detection of Papillary Bladder Cancer and Early Recurrence rate in Patients with Bladder Cancer.
New York; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
New York; Columbia University
The main purpose of this research study is to evaluate the safety and dosing of an investigational gene transfer agent called CG0070 and to see if it has an effect on superficial bladder cancer that does not respond to prior BCG (bacillus Calmette-Guerin) treatment.
North Carolina
CHARLOTTE; CAROLINAS HEMATOLOGY ONCOLOGY ASSOCIATES
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Charlotte; Carolinas Hematology Oncology Associates
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Charlotte; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Durham; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Ohio
Cincinnati; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
CLEVELAND; TAUSSIG CANCER CENTER
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
COLUMBUS; MID-OHIO ONCOLOGY/HEMATOLOGY, INC.
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Columbus; Mid-Ohio Oncology/Hematology, Inc.
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Pennsylvania
Philadelphia; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
PHILADEPHIA; UNIVERSITY OF PENNSYLVANIA
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Philadephia; University Of Pennsylvania
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Pittsburgh; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
SAYRE; GUTHRIE CLINIC
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Sayre; Guthrie Clinic
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Rhode Island
Providence; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
South Carolina
Greenville; Cancer Center of the Carolinas
The main purpose of this research study is to evaluate the safety and dosing of an investigational gene transfer agent called CG0070 and to see if it has an effect on superficial bladder cancer that does not respond to prior BCG (bacillus Calmette-Guerin) treatment.
Tennessee
GERMANTOWN; C. MICHAEL JONES MD, PC-- THE JONES CLINIC
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
MEMPHIS; THE WEST CLINIC
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Memphis; The West Clinic
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Nashville; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Texas
Corpus Christi; Cancer Specialists Of South Texas, Pa
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Dallas; Mary Crowley Medical Research Center
The main purpose of this research study is to evaluate the safety and dosing of an investigational gene transfer agent called CG0070 and to see if it has an effect on superficial bladder cancer that does not respond to prior BCG (bacillus Calmette-Guerin) treatment.
FORT WORTH; THE CENTER FOR CANCER AND BLOOD DISORDERS
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Fort Worth; The Center For Cancer And Blood Disorders
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Bladder
SAN ANTONIO; SOUTH TEXAS ONCOLOGY & HEMATOLOGY, P.A.
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
San Antonio; South Texas Oncology & Hematology, P.A.
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Virginia
ABINGDON; CANCER OUTREACH ASSOCIATION
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Abingdon; Cancer Outreach Association
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
NEWPORT NEWS; VIRGINIA ONCOLOGY ASSOCIATES
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Norfolk; Virginia Oncology Associates
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Washington
SEATTLE; BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
SEATTLE; UNIVERSITY OF WASHINGTON
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Seattle; Virginia Mason Med Ctr
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Seattle; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Washington, DC
Washington; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
West Virginia
MORGANTOWN; WEST VIRGINIA UNIVERSITY
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
Morgantown; West Virginia University
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine
± Vinflunine in Patients Ineligible to Receive Cisplastin-Based Therapy
International
Adelaide, South Australia, Australia; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Sydney, New South Wales, Australia; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Waratah, New South Wales, Australia; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Linz, Austria; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Salzburg, Austria; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Barrie, ON, Canada; Male/Female Health and Research Centre
The main purpose of this research study is to evaluate the safety and dosing of an investigational gene transfer agent called CG0070 and to see if it has an effect on superficial bladder cancer that does not respond to prior BCG (bacillus Calmette-Guerin) treatment.
Various Cities, Canada; The Female Male Health Center
The main purpose of this research study is to evaluate the safety and dosing of an investigational gene transfer agent called CG0070 and to see if it has an effect on superficial bladder cancer that does not respond to prior BCG (bacillus Calmette-Guerin) treatment.
Caen, France; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Le Mans Cedex 2, France; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Nice, France; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Paris, France; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Toulouse, France; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Jakarta, Indonesia; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Genova, Italy; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Milan, Italy; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Rome, Italy; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Viterbo, Italy; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Seoul, Korea; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Cebu City, Philippines; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Quezon, Philippines; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Quezon City, Philippines; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Singapore, Singapore; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Murcia, Spain; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Palma De Mallorca, Spain; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Santander, Spain; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Linkoping, Sweden; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Uppsala, Sweden; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Aarau, Switzerland; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
Bangkok, Thailand; Research Site
A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium
